Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Monotherapy in Japanese Subjects With Relapsed or Refractory Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma
NCT07387471Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2026
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in Waldenström macroglobulinemia (WM), Lymphoplasmacytic Lymphoma (LPL), sponsored by AbbVie Inc.. Started Mar 2026; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
Waldenström macroglobulinemia (WM)Lymphoplasmacytic Lymphoma (LPL)
Beyond the preview
Go deeper on NCT07387471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07387471.